Literature DB >> 18990435

Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.

Andreas du Bois1, Justine Rochon, Jacobus Pfisterer, William J Hoskins.   

Abstract

OBJECTIVE: Ovarian cancer outcome varies among different institutions, regions, and countries. This systematic review summarizes the available data evaluating the impact of different physician and hospital characteristics on outcome in ovarian cancer patients.
METHODS: A MEDLINE database search for pertinent publications was conducted and reference lists of each relevant article were screened. Experts in the field were contacted. Selected studies assessed the relationship between physician and/or hospital specialty or volume and at least one of the outcomes of interest. The primary outcome was survival. Additional parameters included surgical outcome (debulking), completeness of staging, and quality of chemotherapy. The authors independently reviewed each article and applied the inclusion/exclusion criteria. The quality of each study was assessed by focusing on strategies to control for important prognostic factors.
RESULTS: Forty-four articles met inclusion criteria. Discipline and sub-specialization of the primary treating physician were identified as the most important variable associated with superior outcome. Evidence showing a beneficial impact of institutional factors was weaker, but followed the same trend. Hospital volume was hardly related to any outcome parameter.
CONCLUSIONS: The limited evidence available showed considerable heterogeneity and has to be interpreted cautiously. Better utilization of knowledge about institutional factors and well-established board certifications may improve outcome in ovarian cancer. Patients and primary-care physicians should select gynecologic oncologists for primary treatment in countries with established sub-specialty training. Policymakers, insurance companies, and lay organizations should support development of respective programs.

Entities:  

Mesh:

Year:  2008        PMID: 18990435     DOI: 10.1016/j.ygyno.2008.09.036

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  39 in total

1.  Emerging concerns when evidence-based medicine is translated into real life: the case of neoadjuvant chemotherapy in ovarian cancer.

Authors:  Antonio González-Martín; Luis Chiva
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

Review 2.  First-line and maintenance therapy for ovarian cancer: current status and future directions.

Authors:  Antonio González-Martín; Luisa Sánchez-Lorenzo; Raquel Bratos; Raúl Márquez; Luis Chiva
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  Apical support at the time of hysterectomy for uterovaginal prolapse.

Authors:  Kelly L Kantartzis; Lindsay C Turner; Jonathan P Shepherd; Li Wang; Daniel G Winger; Jerry L Lowder
Journal:  Int Urogynecol J       Date:  2014-09-03       Impact factor: 2.894

4.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

5.  Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

Authors:  Megan E V Caram; Tudor Borza; Hye-Sung Min; Jennifer J Griggs; David C Miller; Brent K Hollenbeck; Bhramar Mukherjee; Ted A Skolarus
Journal:  J Oncol Pract       Date:  2017-06-19       Impact factor: 3.840

6.  Quality Indicators and Survival Outcome in Stage IIIB-IVB Epithelial Ovarian Cancer Treated at a Single Institution.

Authors:  Inga Steinberga; Kjell Jansson; Bengt Sorbe
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

7.  Experience with sunitinib in the treatment of metastatic renal cell carcinoma.

Authors:  Manuela Schmidinger; James Larkin; Alain Ravaud
Journal:  Ther Adv Urol       Date:  2012-10

8.  Ovarian cancer in the United States: contemporary patterns of care associated with improved survival.

Authors:  William A Cliby; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2014-10-29       Impact factor: 5.482

9.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

Review 10.  The optimal organization of gynecologic oncology services: a systematic review.

Authors:  M Fung-Kee-Fung; E B Kennedy; J Biagi; T Colgan; D D'Souza; L M Elit; A Hunter; J Irish; R McLeod; B Rosen
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.